Tyra Biosciences (TYRA) News Today $13.48 -0.19 (-1.35%) As of 11:42 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TYRA Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Tyra Biosciences (NASDAQ:TYRA) Raised to "Hold" at Wall Street ZenOctober 4 at 3:09 AM | marketbeat.comTyra Biosciences, Inc. $TYRA Shares Sold by Canaan Partners XI LLCSeptember 30, 2025 | marketbeat.comTyra Biosciences (NASDAQ:TYRA) Cut to Sell at Wall Street ZenSeptember 27, 2025 | americanbankingnews.comTyra Biosciences (NASDAQ:TYRA) Downgraded to Sell Rating by Wall Street ZenSeptember 27, 2025 | marketbeat.comAdvanced Liver Cancer Clinical Trial Pipeline Shows Potential with Active Contributions from 50+ Key Companies | DelveInsightSeptember 25, 2025 | finance.yahoo.comTyra Biosciences, Inc. (NASDAQ:TYRA) Receives Average Rating of "Buy" from BrokeragesSeptember 15, 2025 | marketbeat.comTyra Biosciences (NASDAQ:TYRA) Upgraded by Wall Street Zen to "Hold" RatingSeptember 15, 2025 | marketbeat.comTyra Biosciences, Inc. $TYRA Shares Acquired by Jacobs Levy Equity Management Inc.September 12, 2025 | marketbeat.comTyra Biosciences price target raised to $36 from $30 at OppenheimerSeptember 10, 2025 | msn.comPolar Asset Management Partners Inc. Has $1.31 Million Stock Holdings in Tyra Biosciences, Inc. $TYRASeptember 9, 2025 | marketbeat.comNMIBC Pipeline Outlook 2025: Insights Into Therapies, Research, and Market PotentialSeptember 8, 2025 | theglobeandmail.comNuveen LLC Acquires New Stake in Tyra Biosciences, Inc. $TYRASeptember 7, 2025 | marketbeat.comWe're Hopeful That Tyra Biosciences (NASDAQ:TYRA) Will Use Its Cash WiselySeptember 6, 2025 | finance.yahoo.comTyra Biosciences, Inc. $TYRA Shares Sold by Ally Bridge Group NY LLCSeptember 5, 2025 | marketbeat.comTyra Biosciences, Inc. $TYRA Shares Purchased by Vestal Point Capital LPSeptember 4, 2025 | marketbeat.comTyra Biosciences management to meet with OppenheimerSeptember 4, 2025 | msn.comRaymond James Initiates Coverage of Tyra Biosciences (TYRA) with Strong Buy RecommendationSeptember 4, 2025 | msn.comTyra Biosciences initiated with a Strong Buy at Raymond JamesSeptember 3, 2025 | msn.comWalleye Capital LLC Has $1.31 Million Stake in Tyra Biosciences, Inc. $TYRASeptember 1, 2025 | marketbeat.comAlphaQuest LLC Raises Stock Holdings in Tyra Biosciences, Inc. $TYRAAugust 31, 2025 | marketbeat.comTyra Biosciences (NASDAQ:TYRA) Earns Buy Rating from HC WainwrightAugust 24, 2025 | marketbeat.comTyra Biosciences initiates paediatric study for achondroplasia treatmentAugust 22, 2025 | finance.yahoo.comTyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric AchondroplasiaAugust 21, 2025 | prnewswire.comTyra Biosciences, Inc. (NASDAQ:TYRA) Receives Consensus Rating of "Buy" from AnalystsAugust 21, 2025 | marketbeat.comTyra Biosciences Announces Participation at Upcoming Investor EventsAugust 20, 2025 | prnewswire.comDelveInsight Business Research, LLP: FGFR Inhibitors Market Set to Surge by 2034 as Targeted Cancer Therapies Transform Treatment Paradigms | DelveInsightAugust 20, 2025 | finanznachrichten.deFGFR Inhibitors Market Set to Surge by 2034 as Targeted Cancer Therapies Transform Treatment Paradigms | DelveInsightAugust 19, 2025 | finance.yahoo.comTyra Biosciences (NASDAQ:TYRA) Shares Gap Up - Here's What HappenedAugust 17, 2025 | marketbeat.comTyra Biosciences (NASDAQ:TYRA) Releases Earnings Results, Beats Estimates By $0.06 EPSAugust 16, 2025 | marketbeat.comTyra Biosciences reports Q2 EPS (47c), consensus (51c)August 14, 2025 | msn.comTyra Biosciences Reports Second Quarter 2025 Financial Results and HighlightsAugust 14, 2025 | prnewswire.comUrothelial Carcinoma Market Set to Expand During the Forecast Period (2025-2034) Amid Rising Incidence and Evolving Therapeutic Landscape | DelveInsightAugust 7, 2025 | uk.finance.yahoo.comTyra Biosciences, Inc. (NASDAQ:TYRA) Sees Significant Growth in Short InterestAugust 2, 2025 | marketbeat.comTyra Biosciences (TYRA) to Release Quarterly Earnings on WednesdayJuly 31, 2025 | marketbeat.comTyra Biosciences, Inc. (NASDAQ:TYRA) Given Consensus Recommendation of "Buy" by BrokeragesJuly 26, 2025 | marketbeat.comTyra Biosciences (NASDAQ:TYRA) Trading Down 3% - Here's WhyJuly 23, 2025 | marketbeat.comTyra Biosciences Announces Fireside Chat on Achondroplasia and Growth Disorders at UBS Biotech Management Live Call SeriesJuly 21, 2025 | prnewswire.comTyra Biosciences (NASDAQ:TYRA) Trading Up 5.7% - Should You Buy?July 16, 2025 | marketbeat.comTyra Biosciences (NASDAQ:TYRA) Stock Price Down 4.9% - What's Next?July 15, 2025 | marketbeat.comTyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025 - MorningstarJuly 9, 2025 | morningstar.comMTyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025July 8, 2025 | prnewswire.comTyra Biosciences (NASDAQ:TYRA) Shares Down 3.3% - What's Next?July 3, 2025 | marketbeat.comTyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302) - FinanzNachrichten.deJuly 2, 2025 | finanznachrichten.deTyra Biosciences' (TYRA) "Buy" Rating Reiterated at HC WainwrightJuly 1, 2025 | marketbeat.comTyra Biosciences, Inc. (NASDAQ:TYRA) Given Consensus Rating of "Buy" by BrokeragesJuly 1, 2025 | marketbeat.comTyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)June 30, 2025 | prnewswire.comTyra Biosciences (NASDAQ:TYRA) Stock Price Up 5.6% - Here's What HappenedJune 23, 2025 | marketbeat.comInsider Selling: Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Sells 9,568 Shares of StockJune 21, 2025 | insidertrades.comTyra Biosciences, Inc. (NASDAQ:TYRA) Director Sells $93,575.04 in StockJune 20, 2025 | marketbeat.comTyra Biosciences, Inc. (NASDAQ:TYRA) Director Sells $70,729.32 in StockJune 17, 2025 | insidertrades.com Get Tyra Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for TYRA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TYRA Media Mentions By Week TYRA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TYRA News Sentiment▼0.880.54▲Average Medical News Sentiment TYRA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TYRA Articles This Week▼24▲TYRA Articles Average Week Get the Latest News and Ratings for TYRA and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Tyra Biosciences and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies HCM News KNSA News OGN News MLYS News ALVO News IBRX News BHC News CPRX News TARS News IDYA News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TYRA) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersWall Street legend: “Sell this A.I. stock now”Whats next after AI? Hidden AI. "Hidden AI" could soon be the biggest investment trend of 2025.Chaikin Analytics | SponsoredThe next wave of AI fortunes may come from NVIDIA’s secret supplier.Bloomberg says AI is a $50 trillion revolution. And at the center of it… isn't NVIDIA. It's a tiny suppl...Behind the Markets | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredIs Nvidia about to Trigger Another 150X Opportunity?Nvidia gave investors a chance to make more than 150 times their money with its AI chips, known as graphics pr...InvestorPlace | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tyra Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tyra Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
